News Releases

May 15, 2019

Summary Toggle X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

Mavorixafor selected for LLS’s Therapy Acceleration Program ® (TAP) CAMBRIDGE, Mass. & RYE BROOK, N.Y. --(BUSINESS WIRE)--May 15, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the...
Read more

PDF Version
April 24, 2019

Summary Toggle X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of E....
Read more

PDF Version
April 12, 2019

Summary Toggle X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 12, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced und...
Read more

PDF Version
April 11, 2019

Summary Toggle X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten publi...
Read more

PDF Version
April 2, 2019

Summary Toggle X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Murray Stewart , M.D., as...
Read more

PDF Version
April 1, 2019

Summary Toggle X4 Pharmaceuticals Provides Business and Clinical Development Update

Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome in second quarter 2019 having finalized the protocol based on FDA guidance Receives World Health Organ...
Read more

PDF Version
March 13, 2019

Summary Toggle X4 Pharmaceuticals Completes Merger with Arsanis

– Newly Nasdaq-listed XFOR focused on the development of novel therapeutics for the treatment of rare diseases – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019 ), a clinical-stage biopharmaceutical company focused ...
Read more

PDF Version